Wednesday, July 8, 2026

pharma · Advanced Cancer · Non-small Cell Lung Cancer · RCUS

Arcus Biosciences

Arcus Biosciences clinical programs — 21 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

3928 Point Eden Way, Hayward, California 94545, US HQ
2015 Founded
655 Employees
Public company Type
RCUS · NYSE Ticker
Company details
Status
Public
HQ
3928 Point Eden Way, Hayward, California 94545, US
Founded
2015
Employees
655
Programs
53
Drugs
25
Patents
30
Intelligence · Clinical Programs

Arcus Biosciences projects

21 ClinicalTrials.gov programs sponsored by Arcus Biosciences.

Arcus Biosciences has 21 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AB680

    Arcus Biosciences

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial
  2. ARC-21(EDGE-Gastric)

    Arcus Biosciences

    Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies

    phase 2 small molecule active

    1 trial
  3. ARC-9

    Arcus Biosciences

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial
  4. Atezolizumab

    Arcus Biosciences

    Prostate Adenocarcinoma

    phase 2 small molecule active

    1 trial
  5. Casdatifan

    Arcus Biosciences

    Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial
  6. Domvanalimab

    Arcus Biosciences

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  7. Domvanalimab

    Arcus Biosciences

    Gastrointestinal Tract Malignancies

    phase 2 small molecule active

    1 trial
  8. Domvanalimab

    Arcus Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  9. Domvanalimab

    Arcus Biosciences

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    2 trials
  10. Etrumadenant

    Arcus Biosciences

    Prostatic Neoplasms, Castration-Resistant

    phase 2 small molecule completed

    1 trial
  11. Etrumadenant (AB928)

    Arcus Biosciences

    Rectal Cancer

    phase 2 small molecule active

    1 trial
  12. Fluorouracil

    Arcus Biosciences

    Borderline Resectable Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial
  13. Gemcitabine

    Arcus Biosciences

    Biliary Tract Carcinoma

    phase 2 small molecule active

    1 trial
  14. Quemliclustat

    Arcus Biosciences

    Oligometastatic Prostate Cancer

    phase 2 small molecule active

    1 trial
  15. SRF617

    Arcus Biosciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial
  16. ZIMBERELIMAB

    Arcus Biosciences

    Pancreatic Cancer

    phase 2 small molecule on hold

    1 trial
  17. Zimberelimab

    Arcus Biosciences

    Adenocarcinoma Stomach

    phase 2 small molecule terminated

    1 trial
  18. Zimberelimab

    Arcus Biosciences

    Hepatobiliary Cancer

    phase 2 small molecule active

    1 trial
  19. Zimberelimab

    Arcus Biosciences

    Melanoma

    phase 2 small molecule active

    1 trial
  20. Zimberelimab

    Arcus Biosciences

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial
  21. Zimberelimab (ZIM)

    Arcus Biosciences

    Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Arcus Biosciences have?

21 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.